UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting RAS–ERK signalling in cancer: promises and challenges

Nature reviews. Drug discovery, 2014-12, Vol.13 (12), p.928-942

2014

Volltextzugriff (PDF)

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Cancer cell, 2015-02, Vol.27 (2), p.240-256

2015

Volltextzugriff (PDF)

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer

Breast cancer research : BCR, 2021-10, Vol.23 (1), p.100-18, Article 100

2021

Volltextzugriff (PDF)

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

Journal of medicinal chemistry, 2021-09, Vol.64 (17), p.13004-13024

2021

Volltextzugriff (PDF)

Dissecting Therapeutic Resistance to ERK Inhibition

Molecular cancer therapeutics, 2016-04, Vol.15 (4), p.548-559

2016

Volltextzugriff (PDF)

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Cancer biology & therapy, 2006-04, Vol.5 (4), p.419-426

2006

Volltextzugriff (PDF)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Molecular cancer, 2014-08, Vol.13 (1), Article 194

2014

Volltextzugriff (PDF)

Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase

Journal of medicinal chemistry, 2014-11, Vol.57 (21), p.8817-8826

2014

Volltextzugriff (PDF)

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology

Bioorganic & medicinal chemistry letters, 2018-06, Vol.28 (11), p.2029-2034

2018

Volltextzugriff (PDF)

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

ACS medicinal chemistry letters, 2018-07, Vol.9 (7), p.761-767

2018

Volltextzugriff (PDF)

Network-level effects of kinase inhibitors modulate TNF-α-induced apoptosis in the intestinal epithelium

Science signaling, 2015-12, Vol.8 (407), p.ra129

2015

Volltextzugriff (PDF)

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

Pigment cell and melanoma research, 2015-05, Vol.28 (3), p.307-317

2015

Volltextzugriff (PDF)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

Oncotarget, 2016-11, Vol.7 (44), p.71211-71222

2016

Volltextzugriff (PDF)

Abstract 3829: Preclinical development of a combination inhibitor strategy to block K-Ras effector signaling and autophagy for pancreatic cancer treatment

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3829-3829

2016

Volltextzugriff (PDF)

Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers

The Enzymes, 2013, Vol.34, p.67-106

2013

Volltextzugriff (PDF)

Abstract IA06: Discovery of a first-in-class ERK 1,2 inhibitor

Molecular cancer research, 2014-12, Vol.12 (12_Supplement), p.IA06-IA06

Samatar, Ahmed A.

2014

Volltextzugriff (PDF)

Abstract 1965: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1965-1965

2021

Volltextzugriff (PDF)

Abstract 2423: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2423-2423

2021

Volltextzugriff (PDF)

Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4373-4373

2020

Volltextzugriff (PDF)

Abstract 3099: Hnd-01: a potent inhibitor of wild type mutant BTK

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3099-3099

2023

Volltextzugriff (PDF)

Abstract 4660: Inhibition of p38 enhances ERK inhibitor efficacy in pancreatic ductal adenocarcinoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4660-4660

2016

Volltextzugriff (PDF)

Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors

Bioorganic & medicinal chemistry letters, 2015-04, Vol.25 (7), p.1627-1629

2015

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(134)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(144)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(27)
Humans
(22)
Somalia
(16)
Oncology
(12)
Animals
(11)
Cell Line, Tumor
(10)
Protein Kinase Inhibitors - Pharmacology
(10)
Africa
(7)
Biochemistry & Molecular Biology
(6)
Mice
(6)
Pharmacology & Pharmacy
(6)
Cell Biology
(5)
Chemistry, Medicinal
(5)
Life Sciences
(5)
Mutation
(5)
Neoplasms - Drug Therapy
(5)
Social Sciences
(5)
Antineoplastic Agents - Pharmacology
(4)
Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(54)
De Gruyter eBooks
(43)
Publisher or Other Site
(32)
MEDLINE
(26)
JSTOR
(26)
Ingenta
(25)
Project MUSE All Journals
(14)
IngentaConnect Journals
(13)
Nexis Uni
(9)
Springer Journals
(8)
Elsevier ScienceDirect Journals Complete
(7)
Taylor & Francis:Master (3349 titles)
(6)
Taylor & Francis Journals
(6)
Taylor & Francis
(6)
PAIS Index
(5)
Ebook Central Perpetual and DDA
(5)
eBooks on EBSCOhost
(5)
Literature Online (LION)
(5)
Worldwide Political Science Abstracts
(4)
Cambridge Journals Online (DEFF)
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Targeting RAS–ERK signalling in cancer: promises and challenges

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

Dissecting Therapeutic Resistance to ERK Inhibition

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

Network-level effects of kinase inhibitors modulate TNF-α-induced apoptosis in the intestinal epithelium

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

Abstract 3829: Preclinical development of a combination inhibitor strategy to block K-Ras effector signaling and autophagy for pancreatic cancer treatment

Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers

Abstract IA06: Discovery of a first-in-class ERK 1,2 inhibitor

Abstract 1965: Discovery of ZN-c3, a potent Wee-1 inhibitor with a differentiated pharmacologic and kinase selectivity profile

Abstract 2423: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer

Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader

Abstract 3099: Hnd-01: a potent inhibitor of wild type mutant BTK

Abstract 4660: Inhibition of p38 enhances ERK inhibitor efficacy in pancreatic ductal adenocarcinoma

Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors

Suchergebnisse filtern